Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Zwenneke Hendrieke Flach"'
Autor:
Renske Gahrmann, Marion Smits, René Michel Vernhout, Walter Taal, Giorgios Kapsas, Jan Cees de Groot, Monique Hanse, Maaike Vos, Laurens Victor Beerepoot, Jan Buter, Zwenneke Hendrieke Flach, Bronno van der Holt, Martin van den Bent
Publikováno v:
Gahrmann, R, Smits, M, Vernhout, R M, Taal, W, Kapsas, G, de Groot, J C, Hanse, M, Vos, M, Beerepoot, L V, Buter, J, Flach, Z H, van der Holt, B & van den Bent, M 2022, ' The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab ', Neuro-oncology advances, vol. 4, no. 1, vdac032 . https://doi.org/10.1093/noajnl/vdac032
Neuro-Oncology Advances, 4(1):vdac032. Oxford University Press
Neuro-oncology advances, 4(1):vdac032. Oxford University Press
Neuro-oncology advances, 4(1):vdac032
Neuro-Oncology Advances, 4(1):vdac032. Oxford University Press
Neuro-oncology advances, 4(1):vdac032. Oxford University Press
Neuro-oncology advances, 4(1):vdac032
Background The optimal volumetric threshold for determining progressive disease (PD) in recurrent glioblastoma is yet to be determined. We investigated a range of thresholds in association with overall survival (OS). Methods First recurrent glioblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0f793e0e28d276a5980a90eead8efa
https://doi.org/10.1093/noajnl/vdac032
https://doi.org/10.1093/noajnl/vdac032
Autor:
Bronno van der Holt, Walter Taal, Zwenneke Hendrieke Flach, Monique Hanse, Bas Jasperse, Jan Buter, Martin J. van den Bent, René M. Vernhout, Marion Smits, Maaike J. Vos, Renske Gahrmann, Jan Cees de Groot, Laurens V. Beerepoot
Publikováno v:
Neuro-Oncology, 19(6), 853-861. Oxford University Press
Gahrmann, R, van den Bent, M, van der Holt, B, Vernhout, R M, Taal, W, Vos, M, de Groot, J C, Beerepoot, L V, Buter, J, Flach, Z H, Hanse, M, Jasperse, B & Smits, M 2017, ' Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial ', Neuro-Oncology, vol. 19, no. 6, pp. 853-861 . https://doi.org/10.1093/neuonc/now311, https://doi.org/10.1093/neuonc/now311
Gahrmann, R, van den Bent, M, van der Holt, B, Vernhout, R M, Taal, W, Vos, M, de Groot, J C, Beerepoot, L V, Buter, J, Flach, Z H, Hanse, M, Jasperse, B & Smits, M 2017, ' Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial ', Neuro-Oncology, vol. 19, no. 6, pp. 853-861 . https://doi.org/10.1093/neuonc/now311, https://doi.org/10.1093/neuonc/now311
Background. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on postcontrast T1-weighted (T1w) M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca94a46a95cb942147567e228da7dcc3
https://doi.org/10.1093/neuonc/now311
https://doi.org/10.1093/neuonc/now311